Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IBSolution
- Development stage
- Unknown
- Lead developer
- AB-BIOTICS
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
IBSolution is a probiotic blend composed of four specific bacterial strains: *Lactobacillus plantarum* CECT30292, *Lactobacillus plantarum* CECT7484, *Lactobacillus plantarum* CECT7485, and *Pediococcus acidilactici* CECT7483. Developed and supplied by AB-Biotics SA, it is marketed as a food supplement for managing symptoms of irritable bowel syndrome (IBS). The blend, typically containing 3 billion colony-forming units (CFU), works by targeting and restoring intestinal permeability and reducing inflammation. Clinical studies have shown its potential to enhance the actin cytoskeleton and upregulate CYP1A1 expression, contributing to improved gut barrier function. [6, 7, 8] Beyond IBS, it has been investigated for its benefits in inflammatory bowel disease (IBD), fructose intolerance, and migraine with concurrent IBS. [9, 12, 18]
- Brand names
- IBSolutionLactoflora IBSolutionProbielle IBSolution
- Other names
- Lactobacillus plantarum CECT30292 + Lactobacillus plantarum CECT7484 + Lactobacillus plantarum CECT7485 + Pediococcus acidilactici CECT7483
Beyond the preview
Go deeper on IBSolution.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IBSolution.